Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 4
Submit an article Journal homepage
132
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Arcelis™ AGS-004 dendritic cell-based immunotherapy for HIV infection

Jean-Pierre Routy1 Montreal Chest Institute, McGill University Health Centre, 3650 Rue St Urbain, Montreal, QC, H2X 2P4, Canada.Tel.: +1 514 934 1934 ext 35883 Fax: +1 514 843 [email protected]View further author information
&
Charles Nicolette1 Argos Therapeutics Inc, Durham, NC, USAView further author information
Pages 467-476 | Published online: 16 Jul 2010

Bibliography

  • Worm SW , De Wit S, Weber R et al.: Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (d:A:D study). Circulation119(6) , 805–811 (2009).
  • Mocroft A , KirkO, GatellJet al.: Chronic renal failure among HIV-1-infected patients.AIDS21(9) , 1119–1127 (2007).
  • Lima VD , HarriganR, BangsbergDRet al.: The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.J. Acquir. Immune Defic. Syndr.50(5) , 529–536 (2009).
  • Steigbigel RT , CooperDA, KumarPNet al.: Raltegravir with optimized background therapy for resistant HIV-1 infection.N. Engl. J. Med.359(4) , 339–354 (2008).
  • Little SJ , HolteS, RoutyJPet al.: Antiretroviral-drug resistance among patients recently infected with HIV.N. Engl. J. Med.347(6) , 385–394 (2002).
  • Sax PE , TierneyC, CollierACet al.: Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy.N. Engl. J. Med.361(23) , 2230–2240 (2009).
  • Kinloch-de Loes S : Role of therapeutic vaccines in the control of HIV-1.J. Antimicrob. Chemother.53(4) , 562–566 (2004).
  • Johnston MI , FauciAS: An HIV vaccine – challenges and prospects.N. Engl. J. Med.359(9) , 888–890 (2008).
  • Sodora DL , AllanJS, ApetreiCet al.: Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts.Nat. Med.15(8) , 861–865 (2009).
  • Cohen OJ , KinterA, FauciAS: Host factors in the pathogenesis of HIV disease.Immunol. Rev.159 , 31–48 (1997).
  • Appay V , DouekDC, PriceDA: CD8+ T cell efficacy in vaccination and disease.Nat. Med.14(6) , 623–628 (2008).
  • Douek DC , RoedererM, KoupRA: Emerging concepts in the immunopathogenesis of AIDS.Annu. Rev. Med.60 , 471–484 (2009).
  • Streeck H , JolinJS, QiYet al.: Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells.J. Virol.83(15) , 7641–7648 (2009).
  • Ndongala M l, Peretz Y, Boulet S et al.: HIV GAG p24 specific responses secreting IFN-γ and/or IL-2 in treatment-naive individuals in acute infection early disease (AIED) are associated with low viral load. Clin. Immunol.131(2) , 277–287 (2009).
  • Saez-Cirion A , LacabaratzC, LambotteOet al.: HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.Proc. Natl Acad. Sci. USA104(16) , 6776–6781 (2007).
  • Pereyra F , AddoMM, KaufmannDEet al.: Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.J. Infect. Dis.197(4) , 563–571 (2008).
  • Boulassel MR , MercierF, GilmoreN, RoutyJP: Immunophenotypic patterns of CD8+ T cell subsets expressing CD8αα and IL-7Rα in viremic, aviremic and slow progressor HIV-1-infected subjects.Clin. Immunol.124(2) , 149–157 (2007).
  • Koup RA , SafritJT, CaoYet al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.J. Virol.68(7) , 4650–4655 (1994).
  • Jin X , BauerDE, TuttletonSEet al.: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques.J. Exp. Med.189(6) , 991–998 (1999).
  • Allen TM , O‘connorDH, JingPet al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.Nature407(6802) , 386–390 (2000).
  • Allen TM , AltfeldM, GeerSCet al.: Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.J. Virol.79(21) , 13239–13249 (2005).
  • Trautmann L , JanbazianL, ChomontNet al.: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.Nat. Med.12(10) , 1198–1202 (2006).
  • Said EA , DupuyFP, TrautmannLet al.: Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.Nat. Med.16(4) , 452–459 (2010).
  • Brenchley JM , PriceDA, SchackerTWet al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection.Nat. Med.12(12) , 1365–1371 (2006).
  • Jiang W , LedermanMM, HuntPet al.: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.J. Infect. Dis.199(8) , 1177–1185 (2009).
  • Naeger DM , MartinJN, SinclairEet al.: Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease.PLoS One5(1) , E8886 (2010).
  • Deeks SG : Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.Top. HIV Med.17(4) , 118–123 (2009).
  • Luo X , TarbellKV, YangHet al.: Dendritic cells with TGF-β1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells.Proc. Natl Acad. Sci. USA104(8) , 2821–2826 (2007).
  • Dalod M , Salazar-MatherTP, MalmgaardLet al.: Interferon αβ and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo.J. Exp. Med.195(4) , 517–528 (2002).
  • Fujii S , LiuK, SmithC, BonitoAJ, SteinmanRM: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation.J. Exp. Med.199(12) , 1607–1618 (2004).
  • Coleman CM , WuL: HIV interactions with monocytes and dendritic cells: viral latency and reservoirs.Retrovirology6 , 51 (2009).
  • Miller CJ , HuJ: T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and langerhans‘ cells of the female genital tract are infected with SIV.J. Infect. Dis.179(Suppl. 3) , S413–S417 (1999).
  • Lambert AA , GilbertC, RichardM, BeaulieuAD, TremblayMJ: The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways.Blood112(4) , 1299–1307 (2008).
  • Steinman RM , BanchereauJ: Taking dendritic cells into medicine.Nature449(7161) , 419–426 (2007).
  • Pulendran B , SmithJL, CasparyGet al.: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo.Proc. Natl Acad. Sci. USA96(3) , 1036–1041 (1999).
  • Banchereau J , SteinmanRM: Dendritic cells and the control of immunity.Nature392(6673) , 245–252 (1998).
  • Steinman RM : Dendritic cells in vivo: a key target for a new vaccine science.Immunity29(3) , 319–324 (2008).
  • Probst HC , MccoyK, OkazakiT, HonjoT, Van Den Broek M: Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol.6(3) , 280–286 (2005).
  • Napolitani G , RinaldiA, BertoniF, SallustoF, LanzavecchiaA: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.Nat. Immunol.6(8) , 769–776 (2005).
  • Gringhuis SI , Van Der Vlist M, Van Den Berg LM, Den Dunnen J, Litjens M, Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-sign for productive infection of dendritic cells. Nat. Immunol.11(5) , 419–426
  • Randolph GJ , AngeliV, SwartzMA: Dendritic-cell trafficking to lymph nodes through lymphatic vessels.Nat. Rev. Immunol.5(8) , 617–628 (2005).
  • Shortman K , NaikSH: Steady-state and inflammatory dendritic-cell development.Nat. Rev. Immunol.7(1) , 19–30 (2007).
  • Nobile C , PetitC, MorisAet al.: Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.J. Virol.79(9) , 5386–5399 (2005).
  • Tacken PJ , De Vries IJ, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10) , 790–802 (2007).
  • Muthumani K , HwangDS, ChooAYet al.: HIV-1 VPR inhibits the maturation and activation of macrophages and dendritic cells in vitro.Int. Immunol.17(2) , 103–116 (2005).
  • Cameron PU , FreudenthalPS, BarkerJM, GezelterS, InabaK, SteinmanRM: Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells.Science257(5068) , 383–387 (1992).
  • Fontaine J , CoutleeF, TremblayC, RoutyJP, PoudrierJ, RogerM: HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease.J. Infect. Dis.199(7) , 1007–1018 (2009).
  • Tcherepanova I , StarrA, LackfordBet al.: The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, r90.PLoS One4(6) , E5853 (2009).
  • Hansen SG , VievilleC, WhizinNet al.: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.Nat. Med.15(3) , 293–299 (2009).
  • Rosenberg ES , BillingsleyJM, CaliendoAMet al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.Science278(5342) , 1447–1450 (1997).
  • Harari A , PetitpierreS, VallelianF, PantaleoG: Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.Blood103(3) , 966–972 (2004).
  • Autran B , CarcelainG, CombadiereB, DebreP: Therapeutic vaccines for chronic infections.Science305(5681) , 205–208 (2004).
  • Banchereau J , PaluckaAK, DhodapkarMet al.: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine.Cancer Res.61(17) , 6451–6458 (2001).
  • O‘Rourke MG , JohnsonM, LanaganCet al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.Cancer Immunol. Immunother.52(6) , 387–395 (2003).
  • Palucka AK , UenoH, ConnollyJet al.: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.J. Immunother.29(5) , 545–557 (2006).
  • Lu W , WuX, LuY, GuoW, AndrieuJM: Therapeutic dendritic-cell vaccine for simian AIDS.Nat. Med.9(1) , 27–32 (2003).
  • Kundu SK , EnglemanE, BenikeCet al.: A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.AIDS Res. Hum. Retroviruses14(7) , 551–560 (1998).
  • Lu W , ArraesLC, FerreiraWT, AndrieuJM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.Nat. Med.10(12) , 1359–1365 (2004).
  • Garcia F , LejeuneM, ClimentNet al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.J. Infect. Dis.191(10) , 1680–1685 (2005).
  • Ide F , NakamuraT, TomizawaMet al.: Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a Phase I trial.J. Med. Virol.78(6) , 711–718 (2006).
  • Connolly NC , WhitesideTL, WilsonC, KondraguntaV, RinaldoCR, RiddlerSA: Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.Clin. Vaccine Immunol.15(2) , 284–292 (2008).
  • Gandhi RT , O‘NeillD, BoschRJet al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.Vaccine27(43) , 6088–6094 (2009).
  • Marovich MA , MascolaJR, EllerMAet al.: Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.J. Infect. Dis.186(9) , 1242–1252 (2002).
  • Kloverpris H , KarlssonI, BondeJet al.: Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.AIDS23(11) , 1329–1340 (2009).
  • Addo MM , YuXG, RosenbergES, WalkerBD, AltfeldM: Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.DNA Cell Biol.21(9) , 671–678 (2002).
  • Altfeld M , AddoMM, EldridgeRLet al.: Vpr is preferentially targeted by CTL during HIV-1 infection.J. Immunol.167(5) , 2743–2752 (2001).
  • Quaranta MG , MattioliB, GiordaniL, VioraM: The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of aids.FASEB J.20(13) , 2198–2208 (2006).
  • Tcherepanova I , HarrisJ, StarrAet al.: Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.PLoS One3(1) , E1489 (2008).
  • Nicolette CA , HealeyD, TcherepanovaIet al.: Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.Vaccine25(Suppl. 2) , B47–B60 (2007).
  • Debenedette MA , CalderheadDM, KetteringhamHet al.: Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.J. Immunol.181(8) , 5296–5305 (2008).
  • Routy JP , BoulasselMR, Yassine-DiabBet al.: Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.Clin. Immunol.134(2) , 140–147 (2010).
  • Jacobson JM , Pat Bucy R, Spritzler J et al.: Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J. Infect. Dis.194(5) , 623–632 (2006).
  • Lebouche B , TremblayP, QuesnelMet al.: Participants‘ perceptions and representations after dendritic cell immunotherapy and HAART discontinuation in the CTN 239 study.Can. J. Infect. Dis. Med. Microbiol.21(Suppl. B) , 73 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.